|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
ES2134639T3
(es)
*
|
1995-10-10 |
1999-10-01 |
Pfizer |
Antagonistas del receptor de nk-1 para la prevencion de la inflamacion neurologica en terapia de genes.
|
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
JP2004517806A
(ja)
*
|
2000-07-03 |
2004-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
|
|
AU2002243905B2
(en)
*
|
2001-01-26 |
2007-11-08 |
Emory University |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
AU2002305716B2
(en)
*
|
2001-05-23 |
2007-10-25 |
Bristol-Myers Squibb Company |
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
|
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
US20060093612A1
(en)
*
|
2002-05-02 |
2006-05-04 |
Srivastava Pramod K |
Use of heat shock proteins to enhance efficacy of antibody therapeutics
|
|
JP2007511507A
(ja)
*
|
2003-11-14 |
2007-05-10 |
ジェンベク、インコーポレイティッド |
癌を処置するための治療レジメン
|
|
WO2007120542A2
(en)
|
2006-03-30 |
2007-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid library and aav capsid proteins
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
AU2007354917B2
(en)
|
2006-09-26 |
2013-06-06 |
Access To Advanced Health Institute |
Vaccine composition containing synthetic adjuvant
|
|
WO2009058564A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Maxygen, Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
JP5830015B2
(ja)
|
2009-06-05 |
2015-12-09 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
合成グルコピラノシル脂質アジュバント
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
EP2621514B1
(en)
|
2010-09-28 |
2016-09-21 |
KAHR Medical (2005) Ltd |
Compositions and methods for treatment of hematological malignancies
|
|
AU2012243039B2
(en)
|
2011-04-08 |
2017-07-13 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
SI2811981T1
(sl)
|
2012-02-07 |
2019-08-30 |
Infectious Disease Research Institute |
Izboljšanje adjuvantne formulacije, ki obsegajo TLR4 agoniste in postopki za uporabo le-teh
|
|
BR112014028476A2
(pt)
|
2012-05-16 |
2017-08-01 |
Immune Design Corp |
fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
|
|
WO2014172637A1
(en)
|
2013-04-18 |
2014-10-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
KR102392974B1
(ko)
|
2016-05-16 |
2022-05-02 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
Tlr 작용제를 함유하는 제제 및 사용 방법
|
|
MX385732B
(es)
|
2016-06-01 |
2025-03-18 |
Infectious Disease Res Inst |
Partículas de nanoalumbre que contienen un agente de dimensionamiento.
|
|
EP3678695A1
(en)
|
2017-09-08 |
2020-07-15 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|